Bringing new therapeutics to patients via our unique macrocyclic drug discovery platform. GyreOx Limited is a 2019 spinout from the University of Oxford. Incorporated on 20 May 2019, with the laboratories located at the Harwell Campus in Oxfordshire. GyreOx’s platform technology is a combined chemistry / synthetic biology process, protected by 4 patent applications, allowing rapid access to novel and drug-like gyrocycles for hit-to-lead drug discovery. Our proprietary discovery platform is used to create unique and highly modified macrocyclic compounds called ‘gyrocycles’. Gyrocycles combine the target-engagement power of biologics with the cell-entry ability of small molecules.